Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - Foley Trasimene Acquisition IItm2025074d14_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - Foley Trasimene Acquisition IItm2025074d14_ex99-1.htm
EX-10.6 - EXHIBIT 10.6 - Foley Trasimene Acquisition IItm2025074d14_ex10-6.htm
EX-10.5 - EXHIBIT 10.5 - Foley Trasimene Acquisition IItm2025074d14_ex10-5.htm
EX-10.4 - EXHIBIT 10.4 - Foley Trasimene Acquisition IItm2025074d14_ex10-4.htm
EX-10.3 - EXHIBIT 10.3 - Foley Trasimene Acquisition IItm2025074d14_ex10-3.htm
EX-10.2 - EXHIBIT 10.2 - Foley Trasimene Acquisition IItm2025074d14_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - Foley Trasimene Acquisition IItm2025074d14_ex10-1.htm
EX-4.1 - EXHIBIT 4.1 - Foley Trasimene Acquisition IItm2025074d14_ex4-1.htm
EX-3.1 - EXHIBIT 3.1 - Foley Trasimene Acquisition IItm2025074d14_ex3-1.htm

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

 

 

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 18, 2020

 

FOLEY TRASIMENE ACQUISITION CORP. II

(Exact name of registrant as specified in its charter)

 

Delaware 001-39456 85-1961020
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer Identification No.)
incorporation)    

 

1701 Village Center Circle
Las Vegas, NV
  89134
(Address of principal executive offices)  (Zip Code)

 

(702) 323-7330
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbols   Name of Each Exchange
on Which Registered
Units, each consisting of one share of Class A Common Stock and one-third of one Warrant   BFT.U   The New York Stock Exchange
         
Class A Common Stock, par value $0.0001 per share   BFT   The New York Stock Exchange
         
Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share   BFT WS   The New York Stock Exchange

 

  xIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    
  ¨If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 8.01Other Events.

 

On August 18, 2020, the Registration Statement on Form S-1 (File No. 333-240285) (the “Registration Statement”) relating to the initial public offering (the “IPO”) of Foley Trasimene Acquisition Corp. II (the “Company”) was declared effective by the U.S. Securities and Exchange Commission, and the Company subsequently filed on August 18, 2020, a registration statement on Form S-1 (File No. 333-248116) pursuant to Rule 462(b) under the Securities Act of 1933, as amended, which was effective immediately upon filing. On August 21, 2020, the Company consummated the IPO of 130,000,000 units (the “Units”). Each Unit consists of one share of Class A common stock of the Company, par value $0.0001 per share (“Common Stock”), and one-third of one redeemable warrant of the Company, each whole warrant entitling the holder thereof to purchase one share of Class A Common Stock at an exercise price of $11.50 per share. The Units were sold at a price of $10.00 per share, generating gross proceeds to the Company of $1,300,000,000.

 

On August 18, 2020, the Company effected a stock dividend with respect to the Company’s Class B common stock, par value $0.0001 per share, of 2,875,000 shares thereof, resulting in the Company’s initial stockholders holding an aggregate of 37,375,000 founder shares.

 

Substantially concurrently with the closing of the IPO, the Company completed the private sale of 18,666,667 warrants (the “Private Placement Warrants”) at a purchase price of $1.50 per Private Placement Warrant, to the Company’s sponsor, Trasimene Capital FT, LP II (the “Sponsor”), generating gross proceeds to the Company of approximately $28,000,000. The Private Placement Warrants are identical to the warrants sold as part of the Units in the IPO, except that, so long as they are held by the Sponsor or its permitted transferees: (i) they will not be redeemable by the Company (except in certain redemption scenarios when the price per share of Common Stock equals or exceeds $10.00 (as adjusted)), (ii) they (including the shares of Common Stock issuable upon exercise of these warrants) may not, subject to certain limited exceptions, be transferred, assigned or sold by the Sponsor until 30 days after the completion of the Company’s initial business combination, (iii) they may be exercised by the holders on a cashless basis, and (iv) they (including the shares of Common Stock issuable upon exercise of these warrants) are entitled to registration rights.

 

A total of $1,300,000,000, comprised of the proceeds from the IPO and the sale of the Private Placement Warrants, were placed in a U.S.-based trust account at JP Morgan Chase Bank, N.A., maintained by Continental Stock Transfer & Trust Company, acting as trustee. Except with respect to interest earned on the funds in the trust account that may be released to the Company to pay its taxes, if any, the proceeds from the IPO will not be released from the trust account until the earliest to occur of: (i) the completion of the Company’s initial business combination, (ii) the redemption of any public shares properly tendered in connection with a stockholder vote to amend the Company’s second amended and restated certificate of incorporation (A) to modify the substance or timing of its obligation to redeem 100% of its public shares if the Company does not complete its initial business combination within 24 months from the closing of the IPO or (B) with respect to any other provisions relating to stockholders' rights or pre-initial business combination activity and (iii) the redemption of all of the Company’s public shares if the Company has not completed its initial business combination within 24 months from the closing of the IPO, subject to applicable law.

 

2

 

 

On August 18, 2020, in connection with the IPO, the Company filed its previously approved Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware and, on the dates referred to below, entered into the following agreements previously filed as exhibits to the Company’s Registration Statement:

 

·A Warrant Agreement, dated August 21, 2020, between the Company and Continental Stock Transfer & Trust Company.

 

·An Investment Management Trust Agreement, dated August 21, 2020, between the Company and Continental Stock Transfer & Trust Company.

 

·A Registration Rights Agreement, dated August 21, 2020, among the Company, the Sponsor and certain other security holders named therein.

 

·A Private Placement Warrants Purchase Agreement, dated August 18, 2020, between the Company and the Sponsor.

 

·An Administrative Services Agreement, dated August 21, 2020, between the Company and Cannae Holdings, Inc.

 

·Letter Agreements, dated August 21, 2020, between the Company and each of its officers and directors and the Sponsor.

 

·Indemnity Agreements, dated August 21, 2020, between the Company and each of its officers and directors.

 

On August 18, 2020, the Company issued a press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing the pricing of the IPO. On August 21, 2020, the Company issued a press release, a copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K, announcing the closing of the IPO.

 

3

 

 

Item 9.01Financial Statements and Exhibits.

 

(d)       Exhibits. The following exhibits are filed with this Form 8-K:

 

Exhibit No.    Description of Exhibits
   
3.1 Second Amended and Restated Certificate of Incorporation.
   
4.1 Warrant Agreement, dated August 21, 2020, between the Company and Continental Stock Transfer & Trust Company.
   
10.1 Investment Management Trust Agreement, dated August 21, 2020, between the Company and Continental Stock Transfer & Trust Company.
   
10.2 Registration Rights Agreement, dated August 21, 2020, among the Company, the Sponsor and certain other security holders named therein.
   
10.3 Private Placement Warrants Purchase Agreement, dated August 18, 2020, between the Company and the Sponsor.
   
10.4 Administrative Services Agreement, dated August 21, 2020, between the Company and Cannae Holdings, Inc.
   
10.5 Form of Letter Agreement, dated August 21, 2020, between the Company and each of its officers and directors and the Sponsor.
   
10.6 Form of Indemnity Agreement, dated August 21, 2020, between the Company and each of its officers and directors.
   
99.1 Press Release, dated August 18, 2020.
   
99.2 Press Release, dated August 21, 2020.

 

4

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Foley Trasimene Acquisition Corp. II
     
     
Date: August 24, 2020 By: /s/ Michael L. Gravelle
  Name: Michael L. Gravelle
  Title: General Counsel and Corporate Secretary

 

5